1. New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies
- Author
-
Yan, Di, Blauvelt, Andrew, Dey, Amit K, Golpanian, Rachel S, Hwang, Samuel T, Mehta, Nehal N, Myers, Bridget, Shi, Zhen-Rui, Yosipovitch, Gil, Bell, Stacie, and Liao, Wilson
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Psoriasis ,Clinical Research ,Autoimmune Disease ,Rare Diseases ,Arthritis ,2.1 Biological and endogenous factors ,Aetiology ,Inflammatory and immune system ,Skin ,Arthritis ,Psoriatic ,Cardiovascular Diseases ,Comorbidity ,Humans ,Molecular Targeted Therapy ,Oncology and Carcinogenesis ,Dermatology & Venereal Diseases ,Clinical sciences - Abstract
Although psoriasis and psoriatic arthritis (PsA) have been classically considered to be diseases of the skin and joints, respectively, emerging evidence suggests that a combination of innate and environmental factors creates widespread immune dysfunction, affecting multiple organ systems. A greater understanding of the pathogenesis of psoriasis and the systemic effects of psoriatic inflammation has allowed for the development of new, more effective treatments. The second portion of this two-part review series examines the comorbidities associated with psoriasis and PsA as well as the most recent advances in targeted systemic therapies for these conditions.
- Published
- 2021